The Experts below are selected from a list of 309 Experts worldwide ranked by ideXlab platform
Peter Bruce-jones - One of the best experts on this subject based on the ideXlab platform.
-
Infection in the elderly: studies with Lomefloxacin.
The American journal of medicine, 1992Co-Authors: Peter Crome, Peter Bruce-jonesAbstract:Results of trials of Lomefloxacin (400 mg once daily) in elderly patients with uncomplicated urinary tract infections, complicated urinary tract infections, acute bacterial exacerbations of chronic bronchitis, and as prophylaxis for transurethral surgical procedures (400 mg single dose) have been analyzed. In patients greater than or equal to 65 years of age with uncomplicated urinary tract infections, the bacterial eradication rate for Lomefloxacin was 100%. In patients with complicated urinary tract infections, the bacterial eradication rate for Lomefloxacin (92.2%) was statistically superior to comparator agents (84.9%, p = 0.012). In elderly patients with acute exacerbations of chronic bronchitis caused predominantly by gram-negative pathogens, Lomefloxacin eradicated 85.2% of pathogens versus 73.8% for amoxicillin (p = 0.004). Lomefloxacin was 98% effective as a prophylactic agent in transurethral surgery. The bacteriologic and clinical efficacy of Lomefloxacin was similar in young and elderly groups of patients. Lomefloxacin appears to be as effective as the comparator drugs in both young and elderly patients.
-
Infection in the elderly: studies with Lomefloxacin.
The American Journal of Medicine, 1992Co-Authors: Peter Crome, Peter Bruce-jonesAbstract:Abstract Results of trials of Lomefloxacin (400 mg once daily) in elderly patients with uncomplicated urinary tract infections, complicated urinary tract infections, acute bacterial exacerbations of chronic bronchitis, and as prophylaxis for transurethral surgical procedures (400 mg single dose) have been analyzed. In patients ≥65 years of age with uncomplicated urinary tract infections, the bacterial eradication rate for Lomefloxacin was 100%. In patients with complicated urinary tract infections, the bacterial eradication rate for Lomefloxacin (92.2%) was statistically superior to comparator agents (84.9%, p=0.012). In elderly patients with acute exacerbations of chronic bronchitis caused predominantly by gram-negative pathogens, Lomefloxacin eradicated 85.2% of pathogens versus 73.8% for amoxicillin (p = 0.004). Lomefloxacin was 98% effective as a prophylactic agent in transurethral surgery. The bacteriologic and clinical efficacy of Lomefloxacin was similar in young and elderly groups of patients. Lomefloxacin appears to be as effective as the comparator drugs in both young and elderly patients.
Peter Crome - One of the best experts on this subject based on the ideXlab platform.
-
Infection in the elderly: studies with Lomefloxacin.
The American journal of medicine, 1992Co-Authors: Peter Crome, Peter Bruce-jonesAbstract:Results of trials of Lomefloxacin (400 mg once daily) in elderly patients with uncomplicated urinary tract infections, complicated urinary tract infections, acute bacterial exacerbations of chronic bronchitis, and as prophylaxis for transurethral surgical procedures (400 mg single dose) have been analyzed. In patients greater than or equal to 65 years of age with uncomplicated urinary tract infections, the bacterial eradication rate for Lomefloxacin was 100%. In patients with complicated urinary tract infections, the bacterial eradication rate for Lomefloxacin (92.2%) was statistically superior to comparator agents (84.9%, p = 0.012). In elderly patients with acute exacerbations of chronic bronchitis caused predominantly by gram-negative pathogens, Lomefloxacin eradicated 85.2% of pathogens versus 73.8% for amoxicillin (p = 0.004). Lomefloxacin was 98% effective as a prophylactic agent in transurethral surgery. The bacteriologic and clinical efficacy of Lomefloxacin was similar in young and elderly groups of patients. Lomefloxacin appears to be as effective as the comparator drugs in both young and elderly patients.
-
Infection in the elderly: studies with Lomefloxacin.
The American Journal of Medicine, 1992Co-Authors: Peter Crome, Peter Bruce-jonesAbstract:Abstract Results of trials of Lomefloxacin (400 mg once daily) in elderly patients with uncomplicated urinary tract infections, complicated urinary tract infections, acute bacterial exacerbations of chronic bronchitis, and as prophylaxis for transurethral surgical procedures (400 mg single dose) have been analyzed. In patients ≥65 years of age with uncomplicated urinary tract infections, the bacterial eradication rate for Lomefloxacin was 100%. In patients with complicated urinary tract infections, the bacterial eradication rate for Lomefloxacin (92.2%) was statistically superior to comparator agents (84.9%, p=0.012). In elderly patients with acute exacerbations of chronic bronchitis caused predominantly by gram-negative pathogens, Lomefloxacin eradicated 85.2% of pathogens versus 73.8% for amoxicillin (p = 0.004). Lomefloxacin was 98% effective as a prophylactic agent in transurethral surgery. The bacteriologic and clinical efficacy of Lomefloxacin was similar in young and elderly groups of patients. Lomefloxacin appears to be as effective as the comparator drugs in both young and elderly patients.
Susan Callery-d’amico - One of the best experts on this subject based on the ideXlab platform.
-
A Controlled Trial of Levofloxacin and Lomefloxacin in the Treatment of Complicated Urinary Tract Infection
Urology, 1998Co-Authors: Ira Klimberg, Clair E. Cox, Cynthia L. Fowler, William King, Sun Sook Kim, Susan Callery-d’amicoAbstract:Abstract Objectives. The efficacy and safety of levofloxacin and Lomefloxacin in complicated urinary tract infections (UTIs) were compared in a randomized, open-label, multicenter study. Methods. Outpatients were randomized to receive levofloxacin (250 mg once daily) for 7 to 10 days or Lomefloxacin (400 mg once daily) for 14 days. Three hundred thirty-six patients (171 with levofloxacin, 165 with Lomefloxacin) were evaluable for microbiologic efficacy, and 461 patients (232 with levofloxacin, 229 with Lomefloxacin) for safety. Results. The overall microbiologic eradication rate of pathogens was 95.5% (168 of 176) for levofloxacin and 91.7% (154 of 168) for Lomefloxacin. Eradication rates with respect to patients were 95.3% (163 of 171) and 92.1% (152 of 165) for levofloxacin and Lomefloxacin, respectively. At the 5 to 9-day post-therapy visit, symptoms were completely resolved in 84.8% of levofloxacin-treated patients and were decreased in 8.2% (93.0% clinical success). Among the Lomefloxacin-treated patients, complete resolution was seen in 82.4%, with decreased symptoms in 6.1% (88.5% clinical success). Drug-related adverse events (AEs) were reported by 10 (2.6%) and 18 (5.2%) levofloxacin- and Lomefloxacin-treated patients, respectively. Compared with levofloxacin-treated patients, more Lomefloxacin-treated patients experienced photosensitivity reactions (3 [1.3%] versus 0) and dizziness (2 [0.9%] versus 0). Nausea (3 [1.3%] versus 1 [0.4%]) was more frequent in the levofloxacin-treated group. Six patients in each treatment group had a gastrointestinal AE (1.7%); rash was reported more frequently with Lomefloxacin (4 patients [0.4%]) than with levofloxacin (1 patient [0.4%]). Discontinuation because of AEs was observed in 8 (3.4%) levofloxacin- and 14 (6.1%) Lomefloxacin-treated patients. Conclusions. Once-daily levofloxacin is as effective as and has a superior tolerability profile than Lomefloxacin in the treatment of complicated UTIs.
T. Sudoh - One of the best experts on this subject based on the ideXlab platform.
-
Effect of ranitidine on renal clearance of Lomefloxacin
European journal of clinical pharmacology, 1996Co-Authors: T. Sudoh, Akio Fujimura, Kazuhiro Harada, K. Sunaga, Masami Ohmori, K. SakamotoAbstract:Objective : To examine the effect of ranitidine on the renal clearance of Lomefloxacin. Setting : Department of Clinical Pharmacology, Jichi Medical School. Methods : Lomefloxacin 200 mg and ranitidine 300 mg or its placebo were given orally in a randomised, double-blind, crossover design. Blood and urine samples were obtained during a 24-h period after dosing. Results : The area under the plasma concentration-time curve and the elimination half-life of Lomefloxacin were significantly increased following coadministration with ranitidine. These effects were caused by significant decreases in total (7.8%) and renal (22%) clearance of Lomefloxacin. In contrast, creatinine clearance and urinary excretion of electrolytes were not influenced by ranitidine. Conclusion : As Lomefloxacin and ranitidine are excreted in urine by renal tubular secretion, the present results suggest that the renal tubular secretion of Lomefloxacin is diminished by ranitidine. As the reduction in Lomefloxacin clearance is only marginal, it is probable that the drug interaction observed in this study is not of clinical significance.
-
Renal clearance of Lomefloxacin is decreased by furosemide.
European journal of clinical pharmacology, 1994Co-Authors: T. Sudoh, Akio Fujimura, Kyoichi Ohashi, T. Shiga, Masato Sasaki, Kazuhiro Harada, Tomonori Tateishi, A. EbiharaAbstract:The interaction between Lomefloxacin, a new quinolone, and furosemide, a loop diuretic, has been examined. Oral Lomefloxacin 200 mg and furosemide 40 mg were given together or separately to 8 healthy subjects, and blood and urine samples were obtained over the following 12 h. The plasma concentrations of Lomefloxacin following coadministration with furosemide were higher than after Lomefloxacin alone and its AUC was increased, and its total and renal clearances were decreased. No change in the pharmacokinetics of furosemide was found after coadministration of Lomefloxacin. As quinolones and furosemide are reported to be excreted in urine by the renal tubular anion transport system, the present results suggest that the renal tubular secretion of Lomefloxacin is diminished by furosemide. It is not clear whether this pharmacokinetic interaction might be clinically important.
J M Conly - One of the best experts on this subject based on the ideXlab platform.
-
treatment of acute uncomplicated urinary tract infections with 3 days of Lomefloxacin compared with treatment with 3 days of norfloxacin
Antimicrobial Agents and Chemotherapy, 1993Co-Authors: Lindsay E Nicolle, J Dubois, A Martel, G K M Harding, S D Shafran, J M ConlyAbstract:The bacteriologic and clinical efficacies of 3 days of Lomefloxacin therapy were compared with those of 3 days of norfloxacin therapy for the treatment of acute uncomplicated urinary tract infections in a prospective, randomized, double-blind study. One hundred sixty-four subjects were enrolled at five Canadian centers; 84 received Lomefloxacin, and 80 received norfloxacin. Escherichia coli (84%) and Staphylococcus saprophyticus (11%) were the most common organisms isolated. Forty subjects (24%) had low quantitative counts in their pretherapy urine specimens. In the intent-to-treat analysis, 76 Lomefloxacin subjects (91%) and 76 norfloxacin subjects (95%) were cured or improved at follow-up 5 to 9 days posttreatment and 73 (87%) and 71 (89%) subjects from the Lomefloxacin and norfloxacin groups, respectively, were cured or improved at 4 to 6 weeks posttreatment. Bacteriologic eradication occurred in 61 of 63 Lomefloxacin subjects (97%) with > or = 10(8) CFU/liter in their pretherapy specimens and 56 of 59 norfloxacin subjects (95%) at 5 to 9 days and 55 (87%) and 53 (90%) subjects from the Lomefloxacin and norfloxacin groups, respectively, at 4 to 6 weeks. There were no statistically significant differences in outcome. Adverse effects which were potentially related to the study medications were reported by 26% of the subjects who received Lomefloxacin and 25% of the subjects who received norfloxacin. There were no severe adverse events, and only one subject discontinued therapy. These data suggest that 3 days of therapy with either Lomefloxacin or norfloxacin is effective in the treatment of acute uncomplicated urinary tract infections.
